Asset Management One Co. Ltd. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,749 shares of the medical research company's stock after selling 2,328 shares during the period. Asset Management One Co. Ltd.'s holdings in IQVIA were worth $13,708,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in IQV. SFE Investment Counsel grew its position in shares of IQVIA by 4.1% during the fourth quarter. SFE Investment Counsel now owns 17,629 shares of the medical research company's stock worth $3,464,000 after acquiring an additional 690 shares during the last quarter. Great Lakes Retirement Inc. grew its position in shares of IQVIA by 6.2% during the fourth quarter. Great Lakes Retirement Inc. now owns 3,055 shares of the medical research company's stock worth $600,000 after acquiring an additional 179 shares during the last quarter. Compound Global Advisors LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $334,000. Peterson Wealth Services grew its position in shares of IQVIA by 19.6% during the fourth quarter. Peterson Wealth Services now owns 1,860 shares of the medical research company's stock worth $366,000 after acquiring an additional 305 shares during the last quarter. Finally, Summit Trail Advisors LLC grew its position in shares of IQVIA by 46.3% during the fourth quarter. Summit Trail Advisors LLC now owns 1,855 shares of the medical research company's stock worth $365,000 after acquiring an additional 587 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Price Performance
IQVIA stock traded up $3.39 during midday trading on Wednesday, reaching $196.54. 1,702,945 shares of the company were exchanged, compared to its average volume of 1,412,729. The company has a market capitalization of $34.61 billion, a price-to-earnings ratio of 26.21, a P/E/G ratio of 1.98 and a beta of 1.48. The firm's 50-day simple moving average is $199.95 and its 200-day simple moving average is $217.09. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.86 EPS for the current year.
Wall Street Analyst Weigh In
IQV has been the topic of a number of research reports. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Barclays decreased their price target on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Finally, Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target for the company. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $251.22.
Read Our Latest Research Report on IQVIA
Insider Buying and Selling at IQVIA
In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company's stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
